Abstract
Leishmaniasis is one of the biggest health problems in the world. Traditional therapeutic methods still depend on a small range of products, mostly chemically. However, the treatment with these drugs is expensive and can cause serious adverse effects, and they have inconsistent effectiveness due to the resistance of parasites to these drugs. The treatment of leishmanial disease has always been a challenge for researchers. The development of nanoscale metals such as silver has attracted significant attention in the field of medicine. The unique characteristic features of silver nanoparticles (AgNPs) make them effective antileishmanial agents. In recent years, green nanotechnology has provided the development of green nanoparticle-based treatment methods for Leishmaniasis. Although there are many studies based on green nanoparticles against Leishmania parasites, this is the first study on the antileishmanial effect of biosynthesized AgNPs using an aqueous extract of Eucalyptus camaldulensis leaves (AEECL) as a reducing agent of silver ions. Different parameters such as AgNO3 concentration, AEECL concentration, and reaction time were studied to investigate the optimum factors for the preparation of stable and small-sized silver nanoparticles. The spherical shape of colloidal nanosilver (CN-Ag) was confirmed by atomic force microscope (AFM) and scanning electron microscope (SEM) images with sizes of 27 and 12 nm, respectively. A high density of nanoparticles with a small size of 10 nm has been confirmed from dynamic light scattering (DLS) analysis. The zeta potential value of 23 mV indicated that colloidal silver nanoparticles were stable. The nano-tracker analysis (NTA) showed the Brownian motion of silver nanoparticles with a hydrodynamic diameter of 31 nm. The antioxidant property of CN-Ag was determined using the stable radical 2,2-Diphenyl-1-picrylhydrazyl (DPPH) assay. In this study, a significant cytotoxic effect of biosynthesized CN-Ag has been shown against Leishmania tropica parasites at low concentrations (1.25, 2.5, and 3.75 µg/mL). These results could be used as a future alternative drug or could be a supportive treatment for Leishmaniasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
